Effects of the 5-HT3 Antagonist, Ondansetron, on the Behavioral and Physiological Effects of Pentagastrin in Patients with Panic Disorder and Social Phobia

A Rating Instrument For Anxiety Disorders

1971 • 3,805 citations

Immunochemical evidence of cholecystokinin-like peptides in brain

1976 • 676 citations

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.

1990 • 501 citations

Increased Anxiogenic Effects of Caffeine in Panic Disorders

1985 • 427 citations

Isolation, structure and biological activity of two cholecystokinin octapeptides from sheep brain

1978 • 426 citations

Lactate Provocation of Panic Attacks

1985 • 381 citations

Enhanced Sensitivity to Cholecystokinin Tetrapeptide in Panic Disorder

1991 • 346 citations

Cholecystokinin Tetrapeptide Induces Panic-like Attacks in Healthy Volunteers

1989 • 322 citations

Carbon Dioxide—Induced Anxiety

1988 • 258 citations

Cholecystokinin and anxiety

1990 • 183 citations

Comparative Distribution of Cholecystokinin and Other Neuropeptides

1985 • 171 citations

Ondansetron Clinical Pharmacokinetics

1995 • 155 citations

Immunoreactive component resembling cholecystokinin octapeptide in intestine

1977 • 153 citations

The behavioural properties of CI‐988, a selective cholecystokinin_B receptor antagonist

1991 • 143 citations

Neurobiology of cholecystokinin.

1994 • 113 citations

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

1994 • 109 citations

Anxiolytic effects of CCK-B antagonists

1991 • 101 citations

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.

1989 • 100 citations

Cholecystokinin release mediated by 5‐HT₃ receptors in rat cerebral cortex and nucleus accumbens

1991 • 97 citations

Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat

1991 • 88 citations

Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses

1994 • 86 citations

Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment

1990 • 84 citations

Heterogeneity of CCK-B receptors involved in animal models of anxiety

1994 • 79 citations

A Comparison of the Effects of Intravenous Pentagastrin on Patients with Social Phobia, Panic Disorder and Healthy Controls

1997 • 77 citations

The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice

1993 • 73 citations

Dose ranging study of the effects of cholecystokinin in healthy volunteers.

1991 • 68 citations

Pharmacology of a cholecystokinin receptor on 5‐hydroxytryptamine neurones in the dorsal raphe of the rat brain

1991 • 66 citations

Satiety and cholecystokinin

1994 • 63 citations

The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze

1993 • 62 citations

Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology

1994 • 58 citations

Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze

1993 • 57 citations

Neuropeptides and anxiety: focus on cholecystokinin

1994 • 50 citations

The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze

1994 • 44 citations

Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder

1991 • 35 citations

Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze

1994 • 24 citations

Peptides and anxiety: A dose‐response evaluation of pentagastrin in healthy volunteers

1994 • 16 citations

Effect of Pentagastrin on Adrenocorticotropin Hormone and Thyroid-Stimulating Hormone Release in Normal Subjects

1983 • 13 citations